Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-108 with Penpulimab and Chemotherapy in Advanced Pancreatic Cancer
NCT06821503Phase 2Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LM-108 in pancreatic cancer (PC) (2 arms), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-limiting toxicity at 28 days and Progression-Free Survival at 48 weeks. Started Apr 2025; status: recruiting.
02
Drugs
LM-108
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06821503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06821503.